Cyclin D3 restricts SARS-CoV-2 envelope incorporation into virions and interferes with viral spread

EMBO J. 2022 Nov 17;41(22):e111653. doi: 10.15252/embj.2022111653. Epub 2022 Oct 10.

Abstract

The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a great threat to human health. The interplay between the virus and host plays a crucial role in successful virus replication and transmission. Understanding host-virus interactions are essential for the development of new COVID-19 treatment strategies. Here, we show that SARS-CoV-2 infection triggers redistribution of cyclin D1 and cyclin D3 from the nucleus to the cytoplasm, followed by proteasomal degradation. No changes to other cyclins or cyclin-dependent kinases were observed. Further, cyclin D depletion was independent of SARS-CoV-2-mediated cell cycle arrest in the early S phase or S/G2/M phase. Cyclin D3 knockdown by small-interfering RNA specifically enhanced progeny virus titres in supernatants. Finally, cyclin D3 co-immunoprecipitated with SARS-CoV-2 envelope (E) and membrane (M) proteins. We propose that cyclin D3 impairs the efficient incorporation of envelope protein into virions during assembly and is depleted during SARS-CoV-2 infection to restore efficient assembly and release of newly produced virions.

Keywords: Fucci; SARS-CoV-2; assembly; cell cycle; cyclin D3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 Drug Treatment
  • COVID-19*
  • Cell Line
  • Cyclin D3
  • Humans
  • Pandemics
  • SARS-CoV-2*
  • Virion

Substances

  • Cyclin D3